The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse.
Identifieur interne : 001005 ( Main/Corpus ); précédent : 001004; suivant : 001006The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse.
Auteurs : Taylor Morrisette ; Thomas P. Lodise ; Marc H. Scheetz ; Srijib Goswami ; Jason M. Pogue ; Michael J. RybakSource :
- Infectious diseases and therapy [ 2193-8229 ] ; 2020.
Abstract
Coronavirus disease 2019 (COVID-19), caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently responsible for a global pandemic. To date, only remdesivir and dexamethasone have demonstrated a positive response in a prospective, randomized trial for the treatment of patients with COVID-19. Hydroxychloroquine (HCQ) is an agent available in an oral formulation with in vitro activity against SARS-CoV-2 that has been suggested as a potential agent. Unfortunately, results of randomized trials evaluating HCQ as treatment against a control group are lacking, and little is known about its pharmacokinetic/pharmacodynamic (PK/PD) profile against SARS-CoV-2. The objective of this review was to describe the current understanding of the PK/PD and dose selection of HCQ against SARS-CoV-2, discuss knowledge gaps, and identify future studies that are needed to optimize the efficacy and safety of treatments against COVID-19.
DOI: 10.1007/s40121-020-00325-2
PubMed: 32740858
PubMed Central: PMC7395206
Links to Exploration step
pubmed:32740858Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse.</title><author><name sortKey="Morrisette, Taylor" sort="Morrisette, Taylor" uniqKey="Morrisette T" first="Taylor" last="Morrisette">Taylor Morrisette</name><affiliation><nlm:affiliation>Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Lodise, Thomas P" sort="Lodise, Thomas P" uniqKey="Lodise T" first="Thomas P" last="Lodise">Thomas P. Lodise</name><affiliation><nlm:affiliation>Albany College of Pharmacy and Health Sciences, Albany, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Scheetz, Marc H" sort="Scheetz, Marc H" uniqKey="Scheetz M" first="Marc H" last="Scheetz">Marc H. Scheetz</name><affiliation><nlm:affiliation>Department of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Pharmacometrics Center of Excellence, Midwestern University, Downers Grove, IL, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pharmacology, College of Graduate Studies, Midwestern University, Downers Grove, IL, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Goswami, Srijib" sort="Goswami, Srijib" uniqKey="Goswami S" first="Srijib" last="Goswami">Srijib Goswami</name><affiliation><nlm:affiliation>InsightRX, San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Pogue, Jason M" sort="Pogue, Jason M" uniqKey="Pogue J" first="Jason M" last="Pogue">Jason M. Pogue</name><affiliation><nlm:affiliation>Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Rybak, Michael J" sort="Rybak, Michael J" uniqKey="Rybak M" first="Michael J" last="Rybak">Michael J. Rybak</name><affiliation><nlm:affiliation>Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA. m.rybak@wayne.edu.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Division of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, MI, USA. m.rybak@wayne.edu.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pharmacy, Detroit Medical Center, Detroit, MI, USA. m.rybak@wayne.edu.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32740858</idno><idno type="pmid">32740858</idno><idno type="doi">10.1007/s40121-020-00325-2</idno><idno type="pmc">PMC7395206</idno><idno type="wicri:Area/Main/Corpus">001005</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001005</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse.</title><author><name sortKey="Morrisette, Taylor" sort="Morrisette, Taylor" uniqKey="Morrisette T" first="Taylor" last="Morrisette">Taylor Morrisette</name><affiliation><nlm:affiliation>Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Lodise, Thomas P" sort="Lodise, Thomas P" uniqKey="Lodise T" first="Thomas P" last="Lodise">Thomas P. Lodise</name><affiliation><nlm:affiliation>Albany College of Pharmacy and Health Sciences, Albany, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Scheetz, Marc H" sort="Scheetz, Marc H" uniqKey="Scheetz M" first="Marc H" last="Scheetz">Marc H. Scheetz</name><affiliation><nlm:affiliation>Department of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Pharmacometrics Center of Excellence, Midwestern University, Downers Grove, IL, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pharmacology, College of Graduate Studies, Midwestern University, Downers Grove, IL, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Goswami, Srijib" sort="Goswami, Srijib" uniqKey="Goswami S" first="Srijib" last="Goswami">Srijib Goswami</name><affiliation><nlm:affiliation>InsightRX, San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Pogue, Jason M" sort="Pogue, Jason M" uniqKey="Pogue J" first="Jason M" last="Pogue">Jason M. Pogue</name><affiliation><nlm:affiliation>Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Rybak, Michael J" sort="Rybak, Michael J" uniqKey="Rybak M" first="Michael J" last="Rybak">Michael J. Rybak</name><affiliation><nlm:affiliation>Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA. m.rybak@wayne.edu.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Division of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, MI, USA. m.rybak@wayne.edu.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pharmacy, Detroit Medical Center, Detroit, MI, USA. m.rybak@wayne.edu.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Infectious diseases and therapy</title><idno type="ISSN">2193-8229</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coronavirus disease 2019 (COVID-19), caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently responsible for a global pandemic. To date, only remdesivir and dexamethasone have demonstrated a positive response in a prospective, randomized trial for the treatment of patients with COVID-19. Hydroxychloroquine (HCQ) is an agent available in an oral formulation with in vitro activity against SARS-CoV-2 that has been suggested as a potential agent. Unfortunately, results of randomized trials evaluating HCQ as treatment against a control group are lacking, and little is known about its pharmacokinetic/pharmacodynamic (PK/PD) profile against SARS-CoV-2. The objective of this review was to describe the current understanding of the PK/PD and dose selection of HCQ against SARS-CoV-2, discuss knowledge gaps, and identify future studies that are needed to optimize the efficacy and safety of treatments against COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32740858</PMID><DateRevised><Year>2020</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2193-8229</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Infectious diseases and therapy</Title><ISOAbbreviation>Infect Dis Ther</ISOAbbreviation></Journal><ArticleTitle>The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse.</ArticleTitle><Pagination><MedlinePgn>561-572</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40121-020-00325-2</ELocationID><Abstract><AbstractText>Coronavirus disease 2019 (COVID-19), caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently responsible for a global pandemic. To date, only remdesivir and dexamethasone have demonstrated a positive response in a prospective, randomized trial for the treatment of patients with COVID-19. Hydroxychloroquine (HCQ) is an agent available in an oral formulation with in vitro activity against SARS-CoV-2 that has been suggested as a potential agent. Unfortunately, results of randomized trials evaluating HCQ as treatment against a control group are lacking, and little is known about its pharmacokinetic/pharmacodynamic (PK/PD) profile against SARS-CoV-2. The objective of this review was to describe the current understanding of the PK/PD and dose selection of HCQ against SARS-CoV-2, discuss knowledge gaps, and identify future studies that are needed to optimize the efficacy and safety of treatments against COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morrisette</LastName><ForeName>Taylor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lodise</LastName><ForeName>Thomas P</ForeName><Initials>TP</Initials><AffiliationInfo><Affiliation>Albany College of Pharmacy and Health Sciences, Albany, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheetz</LastName><ForeName>Marc H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacometrics Center of Excellence, Midwestern University, Downers Grove, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, College of Graduate Studies, Midwestern University, Downers Grove, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goswami</LastName><ForeName>Srijib</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>InsightRX, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pogue</LastName><ForeName>Jason M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rybak</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-1094-043X</Identifier><AffiliationInfo><Affiliation>Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA. m.rybak@wayne.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, MI, USA. m.rybak@wayne.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Detroit Medical Center, Detroit, MI, USA. m.rybak@wayne.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Infect Dis Ther</MedlineTA><NlmUniqueID>101634499</NlmUniqueID><ISSNLinking>2193-6382</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">Pharmacodynamics</Keyword><Keyword MajorTopicYN="N">Pharmacokinetics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32740858</ArticleId><ArticleId IdType="doi">10.1007/s40121-020-00325-2</ArticleId><ArticleId IdType="pii">10.1007/s40121-020-00325-2</ArticleId><ArticleId IdType="pmc">PMC7395206</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation><ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation><ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId></ArticleIdList></Reference><Reference><Citation>Dermatol Ther. 2007 Jul-Aug;20(4):160-74</Citation><ArticleIdList><ArticleId IdType="pubmed">17970883</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Rheumatol. 2018 Dec;14(12):693-703</Citation><ArticleIdList><ArticleId IdType="pubmed">30401979</ArticleId></ArticleIdList></Reference><Reference><Citation>Lung. 2020 Apr;198(2):395-403</Citation><ArticleIdList><ArticleId IdType="pubmed">31960165</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2020 Aug;108(2):253-263</Citation><ArticleIdList><ArticleId IdType="pubmed">32285930</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jun 18;382(25):2411-2418</Citation><ArticleIdList><ArticleId IdType="pubmed">32379955</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Drug Monit. 2003 Dec;25(6):671-81</Citation><ArticleIdList><ArticleId IdType="pubmed">14639053</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 2017 Mar;44(3):398</Citation><ArticleIdList><ArticleId IdType="pubmed">28250164</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2015;70(6):1608-21</Citation><ArticleIdList><ArticleId IdType="pubmed">25693996</ArticleId></ArticleIdList></Reference><Reference><Citation>Agents Actions Suppl. 1988;24:142-57</Citation><ArticleIdList><ArticleId IdType="pubmed">3263755</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatol Ther. 2015 Dec;2(2):183-195</Citation><ArticleIdList><ArticleId IdType="pubmed">27747530</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105954</Citation><ArticleIdList><ArticleId IdType="pubmed">32234467</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 2015 Nov;42(11):2092-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26428205</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Nov 19;71(16):2227-2229</Citation><ArticleIdList><ArticleId IdType="pubmed">32255489</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatol Rehabil. 1976 Aug;15(3):235-8</Citation><ArticleIdList><ArticleId IdType="pubmed">968356</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation><ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Case Rep Cardiol. 2016;2016:4626279</Citation><ArticleIdList><ArticleId IdType="pubmed">27478650</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 1988 Sep;26(3):303-13</Citation><ArticleIdList><ArticleId IdType="pubmed">3179169</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2020 Aug;97:396-403</Citation><ArticleIdList><ArticleId IdType="pubmed">32623082</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105960</Citation><ArticleIdList><ArticleId IdType="pubmed">32251731</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Pharmacol. 1993;44(5):481-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8359187</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Aug 6;383(6):517-525</Citation><ArticleIdList><ArticleId IdType="pubmed">32492293</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Metab Dispos. 2003 Jun;31(6):748-54</Citation><ArticleIdList><ArticleId IdType="pubmed">12756207</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheumatol. 2020 Mar;72(3):448-453</Citation><ArticleIdList><ArticleId IdType="pubmed">31532077</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Netw Open. 2020 Apr 24;3(4):e208857</Citation><ArticleIdList><ArticleId IdType="pubmed">32330277</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Dermatol Venereol. 2018 Jun - Jul;145(6-7):395-404</Citation><ArticleIdList><ArticleId IdType="pubmed">29792286</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 1966 Mar;151(3):482-93</Citation><ArticleIdList><ArticleId IdType="pubmed">4957157</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Sci. 1992 Feb;81(2):155-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1545355</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2009 Apr;53(4):1468-75</Citation><ArticleIdList><ArticleId IdType="pubmed">19188392</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation><ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Sci. 2016 Feb;105(2):884-890</Citation><ArticleIdList><ArticleId IdType="pubmed">26429523</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2020 Oct;108(4):766-769</Citation><ArticleIdList><ArticleId IdType="pubmed">32344449</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 1993 Nov;20(11):1874-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8308772</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 1989 Jun;27(6):771-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2757893</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 May 12;323(18):1824-1836</Citation><ArticleIdList><ArticleId IdType="pubmed">32282022</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheumatol. 2016 Jan;68(1):184-90</Citation><ArticleIdList><ArticleId IdType="pubmed">26316040</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacotherapy. 2020 May;40(5):387-388</Citation><ArticleIdList><ArticleId IdType="pubmed">32285489</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Nov 5;383(19):1813-1826</Citation><ArticleIdList><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Cardiol. 2020 Sep 1;5(9):1036-1041</Citation><ArticleIdList><ArticleId IdType="pubmed">32936252</ArticleId></ArticleIdList></Reference><Reference><Citation>Anticancer Drugs. 1996 Jul;7(5):568-78</Citation><ArticleIdList><ArticleId IdType="pubmed">8862725</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001005 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001005 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32740858
|texte= The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32740858" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |